Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive adults with chronic hepatitis C genotype 1 and HIV-1 coinfection
2008-007995-81Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection and Human immunodeficiency virus infection type 1 comparing Telaprevir + peginterferon alfa-2a + ribavirin with Placebo + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: Safety through Week 12 of dosing and safety follow-up. Started Jan 2010; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-007995-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007995-81.